atrasentan has been researched along with Pulmonary Hypertension in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
| Eshiro, K; Matsumura, Y; Nishida, M; Okada, Y; Takaoka, M | 1 |
| Akiyoshi, K; Eshiro, K; Gariepy, CE; Matsumura, Y; Nishida, M; Okada, Y; Takoaka, M; Yanagisawa, M | 1 |
| Ayach, B; Battistini, B; Blouin, A; Cernacek, P; Jeng, AY; Opgenorth, T; Tsang, J; Verreault, M; Wessale, J | 1 |
| Shi, GY | 1 |
| Demirakca, S; Dieckmann, R; Gebhard, MM; Gorenflo, M; Hagl, S; Herpel, E; Klimpel, H; Neumayer, S; Ullmann, MV | 1 |
| Chen, SJ; Chen, YF; DiCarlo, VS; Durand, J; Meng, QC; Oparil, S; Opgenorth, TJ; Wessale, JL | 1 |
| Chen, YF; Oparil, S | 1 |
| Battistini, B; Cloutier, R; Crochetière, J; Fournier, L; Jean, S; Kavanagh, M; Major, D; Opgenorth, TJ; Wessale, J | 1 |
2 review(s) available for atrasentan and Pulmonary Hypertension
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
7 other study(ies) available for atrasentan and Pulmonary Hypertension
| Article | Year |
|---|---|
Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Body Mass Index; Body Weight; Cardiomegaly; Drug Administration Schedule; Drug Therapy, Combination; Heart; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Injections, Subcutaneous; Intubation, Gastrointestinal; Lung; Male; Monocrotaline; Organ Size; Pulmonary Artery; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Time Factors; Tunica Media; Ventricular Pressure | 2004 |
Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Endothelin B Receptor Antagonists; Hypertension, Pulmonary; Monocrotaline; Pulmonary Artery; Pyrrolidines; Rats; Rats, Mutant Strains; Receptor, Endothelin B; Ventricular Function, Right | 2004 |
Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
Topics: Acute Disease; Animals; Aspartic Acid Endopeptidases; Atrasentan; Benzofurans; Cardiovascular Agents; Disease Models, Animal; Embolism, Air; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-Converting Enzymes; Endothelins; Hemodynamics; Hypertension, Pulmonary; Male; Metalloendopeptidases; Organophosphonates; Protease Inhibitors; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Ventricular Dysfunction, Right | 2004 |
[New choice of therapy of pulmonary hypertension: endothelin receptor antagonist].
Topics: Adult; Atrasentan; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyrimidines; Pyrrolidines; Sulfonamides | 2005 |
Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow.
Topics: Animals; Atrasentan; Blood Pressure; Cardiac Output; Chronic Disease; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Hypertension, Pulmonary; Hypertrophy; Immunohistochemistry; Lung; Pulmonary Artery; Pulmonary Circulation; Pyrrolidines; Random Allocation; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Vascular Endothelial Growth Factor A | 2007 |
The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomegaly; Endothelin Receptor Antagonists; Endothelin-1; Heart Rate; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrrolidines; Rats; Receptor, Endothelin A | 1997 |
Effect of ABT-627 (A-147627), a potent selective ET(A) receptor antagonist, on the cardiopulmonary profile of newborn lambs with surgically-induced diaphragmatic hernia.
Topics: Animals; Animals, Newborn; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Female; Hemodynamics; Hernia, Diaphragmatic; Hypertension, Pulmonary; Infusions, Intravenous; Lung; Matched-Pair Analysis; Oxygen; Pregnancy; Pulmonary Gas Exchange; Pyrrolidines; Receptor, Endothelin A; Respiration; Sheep; Time Factors | 2001 |